The Market Herald - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Impression Healthcare has appointed John Michailidis as CEO of its medicinal hemp drug division
  • John is an experienced executive with a long and successful career in developing medical drugs and bringing them to market
  • Before this role, John worked in multiple companies such as Roche in Korea and Teva Pharmaceuticals
  • Impression’s share price is up 5.63 per cent today with shares currently trading for 7.5 cents apiece

Impression Healthcare has appointed John Michailidis as CEO of its medicinal hemp drug discovery division, Incannex.

John will be joining Dr Sud Agarwal and the Medical Advisory Board to create a market leading cannabinoid pharmaceutical discovery team.

“I’m thrilled to be working alongside John to commercialise our novel clinical assets,” Dr Sud said,

“John brings enthusiasm, vigour and maturity into our drug discovery processes. He has demonstrated solid commercial acumen over his long and successful tenure in the pharmaceutical sector,” he added.

John is an experienced pharmaceutical executive with an extensive and successful career in developing novel drugs and successfully bringing them to market.

He holds a Bachelor of Science (Honours), an executive MBA from Harvard Business School and is a member of The Australian Institute of Company Directors.

Before joining Incannex, John was the founding Managing Director of Teva Pharmaceuticals where he quickly established a significant commercial operation.

In this role, he successfully closed several licensing and partnering deals worth over $10 million per year and increased sales to $100 million by 2017.

John has also spent seven years with world-leading pharmaceutical company Roche Holding AG, where he was the Global Business Director – Strategic Marketing, and before that was President and CEO of Roche Korea.

During his time at Roche Korea, he launched key new treatments into the Korean market, tripled sales in a two-year period and gained patient reimbursement status for various medical treatments.

The company hopes that by appointing John as the CEO of Incannex, it will form part of the continued and significant strengthening of Impression’s drug development team.

“I’m delighted to join a company that is committed to a proper, scientifically principled and sound commercialisation strategy,” John said.

“Dr Sud Agarwal and I are excited to fully develop a world-class medicinal cannabis company to commercialise our novel cannabinoid drugs,” he added.

Impression Healthcare’s share price is up 5.63 per cent today with shares trading for 7.5 cents apiece at 2:35 pm AEDT.

IHL by the numbers
More From The Market Herald

Cynata Therapeutics receives approval to launch phase two trial of CYP-001 in Turkey

Cell therapy company, Cynata Therapeutics (ASX:CYP) has received regulatory and ethics approval to commence a phase…

Little Green Pharma positions itself for growth in France’s emerging medicinal cannabis market

Little Green Pharma (ASX:LGP) is primed for substantial growth after a major amendment to the French…

PolyNovo posts $8m sales month and $9m revenue month for November

Disruptive medical device company PolyNovo (ASX:PNV) has announced record monthly sales of $8.8 million for November…
Imugene (ASX:IMU) - Managing Director & CEO, Leslie Chong

Imugene set to secure European patent for cancer vaccine; announces new phase II CRC cancer trial in 2024

Imugene (ASX:IMU) is on the verge of securing approval from the European Patent Office (EPO) for…